GINSMS Announces Financial Results for the Three and Nine Months Ended September 30, 2022

Written by Customer Service on November 10, 2022. Posted in Earnings Releases And Operating Results.

CALGARY, Alberta., Nov. 10, 2022 (GLOBE NEWSWIRE) — GINSMS Inc. (TSXV: GOK) (the “Corporation”) has announced its financial results for the third quarter ended September 30, 2022. The complete financial results for GINSMS are available at www.sedar.com. Highlights include: Revenue of $789,371 for the three-month period ended September 30, 2022 as compared of $739,706 for the three-month period ended September 30, 2021. Gross Profit of $309,309 for the three-month period ended September 30, 2022 as compared to gross profit of $256,391 for the three-month period ended September 30, 2021. Operating expenses and finance costs of $359,944 for the three-month period ended September 30, 2022 increased from $233,775 for the three-month period ended September 30, 2021. Net loss of $72,257 for three-month period ended September 30, 2022...

Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022

Written by Customer Service on November 10, 2022. Posted in Earnings Releases And Operating Results.

REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, today reported financial results for the three and nine months ended September 30, 2022. Financial Results for the Three Months Ended September 30, 2022 Net loss for the quarter ended September 30, 2022 was $9.8 million compared to $8.0 million for the same period in 2021. Research and development expense for the quarter ended September 30, 2022 was $3.2 million compared to $4.0 million for the same period in 2021. The decrease was primarily due to the August 2022 decision to terminate 20 of its 28 employees and wind-down the GB-102 and GB-401 research and development programs. Restructuring,...

HF Foods Reports Third Quarter 2022 Financial Results

Written by Customer Service on November 10, 2022. Posted in Earnings Releases And Operating Results.

Net Revenue up 40% to $300.7 million LAS VEGAS, Nov. 10, 2022 (GLOBE NEWSWIRE) — HF Foods Group Inc. (NASDAQ: HFFG), a leading food distributor to Asian restaurants across the United States (“HF Foods”, “HF Group” or the “Company”), reported third quarter unaudited financial results for the quarter ended September 30, 2022. The Company is unable to file its unaudited financial results on Form 10-Q due to its ongoing review of complex technical and accounting issues relating to the independent investigation by the Special Investigation Committee of the Company’s Board of Directors, regarding a previously disclosed SEC subpoena and investigation. As previously reported, the Company’s Form 10-K for the year ended December 31, 2021, Form 10-Q for the quarter ended March 31, 2022, and Form 10-Q for the quarter ended June 30, 2022...

Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results

Written by Customer Service on November 10, 2022. Posted in Earnings Releases And Operating Results.

–Reported encouraging clinical data supporting the differentiated mode-of action of Theriva’s novel oncolytic adenovirus (OV) platform– –Received clearance from the Federal Drug Administration (FDA) and Spanish Competent Authority (AEMPS) for the planned Phase 2 clinical trial of systemically administered VCN-01 in Pancreatic Ductal Adenocarcinoma (PDAC) patients– –Reported positive safety and pharmacokinetic data from Cohort 1 of the Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients and dosed the first patient in Cohort 2– –As of September 30, 2022, Theriva Biologics reports $50.5 million in cash, which is expected to provide runway into the first quarter of 2024– –Conference call and webcast to be held on Friday, November 11 at 8:30 a.m. ET– ROCKVILLE, Md., Nov. 10, 2022 (GLOBE...

Canacol Energy Ltd. Reports a 7% Increase in Netback of US$3.73 per Mcf and an Adjusted EBITDAX of $56 million in Q3 2022

Written by Customer Service on November 10, 2022. Posted in Earnings Releases And Operating Results.

CALGARY, Alberta, Nov. 10, 2022 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (“Canacol” or the “Corporation”) (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) is pleased to report its financial and operating results for the three and nine months ended September 30, 2022. Dollar amounts are expressed in United States dollars, with the exception of Canadian dollar unit prices (“C$”) where indicated and otherwise noted. Highlights for the three and nine months ended September 30, 2022 Realized contractual natural gas sales volumes decreased 3% to 184.2 MMscfpd for the three months ended September 30, 2022 and increased 3% to 184.7 MMscfpd for the nine months ended September 30, 2022, compared to 190.6 MMscfpd and 179.9 MMscfpd for the same periods in 2021, respectively. Average natural gas production volumes decreased 3% to 186.7 MMscfpd for the three...

Dave Reports Third Quarter 2022 Financial Results

Written by Customer Service on November 10, 2022. Posted in Earnings Releases And Operating Results.

Record GAAP Operating Revenue and Non-GAAP Operating Revenue, Which Increased 41% Year Over Year Non-GAAP Variable Margin Improved By Approximately 280 Basis Points vs. 2Q22 Dave Card Business Accelerating in 3Q22, Transaction-based revenue up 43% vs. 2Q22 LOS ANGELES, Nov. 10, 2022 (GLOBE NEWSWIRE) — Dave Inc. (Nasdaq: DAVE, DAVEW) (“Dave” or the “Company”), one of the leading U.S. neobanks on a mission to build products that level the financial playing field, today reported its financial results for the third quarter ended September 30, 2022. “We experienced impressive results in the third quarter on all fronts, with record revenue, transacting members and new member growth, along with strong performance of our Dave Card business following the rollout of our new, integrated product experience. Our unit economics are also improving,...

5E Advanced Materials Reports First Quarter 2023 Results

Written by Customer Service on November 10, 2022. Posted in Earnings Releases And Operating Results.

HIGHLIGHTS Small-Scale Boron Facility (“SSBF”) on target for mechanical completion in CY 2022 Board enhanced by appointment of three U.S. based directors with global industry experience Research efforts expanded into boron-based solar energy systems in partnership with Boston College Investor engagement increasing with investor roadshows and 5EA’s inclusion in the S&P/ASX 300 Index Customer discussions and advanced materials strategy advancing on favorable market conditions Balance sheet strengthened to $74.2 million cash ($64.2 million available cash) as of September 30, 2022 HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) — 5E Advanced Materials, Inc. (Nasdaq: FEAM) (ASX: 5EA) (“5E” or the “Company”), a boron and lithium company with U.S. government Critical Infrastructure designation for its 5E Boron Americas...

The Real Good Food Company Reports Third Quarter 2022 Financial Results and Provides Preliminary 2023 Outlook

Written by Customer Service on November 10, 2022. Posted in Earnings Releases And Operating Results.

CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) — The Real Good Food Company, Inc. (Nasdaq: RGF) (“Real Good Foods” or the “Company”), an innovative, high-growth, branded, health- and wellness-focused frozen food company, today reported financial results for its third quarter ended September 30, 2022. Management Commentary Bryan Freeman, Executive Chairman, said: “The categories we compete in continue to grow and have historically performed even better in recessionary periods. Our brand health indicators remain strong, highlighted by continued growth in our brand’s industry leading household penetration rate, which increased to 8.5% this October. The new products we introduced this year (multi-serve Asian Entrees, Breaded Poultry and Breakfast Bowls) continue to gain solid traction as evidenced by strong velocity and the 39K...

Tree Island Steel Announces Third Quarter 2022 Results

Written by Customer Service on November 10, 2022. Posted in Dividend Reports And Estimates.

VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) — Tree Island Steel (”Tree Island” or the ”Company”) (TSX: TSL) announced today its financial results for the nine months ended September 30, 2022. For the three-month period ended September 30, 2022, revenues decreased by $4.4 million to $80.2 million with lower U.S. demand, particularly in the construction and industrial market segments. Gross profit for the third quarter decreased to $14.6 million, from $21.8 million in the same period in 2021 from lower volumes. Adjusted EBITDA amounted to $12.2 million, compared to $20.0 million during the same period in 2021. For the nine months ended September 30, 2022, revenues increased by $45.4 million to $271.3 million when compared to 2021. The increase is primarily due to prior pricing increases across...

Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.

Written by Customer Service on November 10, 2022. Posted in Mergers And Acquisitions.

Special Meeting of stockholders to approve asset sale and merger to be held on December 13, 2022 BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) — Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX) today announced that the registration statement on Form S-4 (the “Registration Statement”), relating to the previously announced asset sale to Janssen Pharmaceutica NV (“Janssen”) and merger with Kineta, Inc. (“Kineta”), has been declared effective by the U.S. Securities and Exchange Commission. In June 2022, the Company announced definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase agreement for the sale of Yumanity’s lead clinical-stage product candidate, YTX-7739, as well as Yumanity’s unpartnered discovery-stage neuroscience product candidates and targets to Janssen,...

Day: November 10, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice